SP Industries Acquires Bel-Art Products
News Jul 02, 2014
SP Industries, Inc. (SP) has announced that it has acquired privately held Bel-Art Products (Bel-Art). Headquartered in Wayne (NJ, USA), Bel-Art is a global provider of innovative laboratory solutions serving the scientific, industrial, and healthcare end markets.
“The acquisition of best-in-class companies that complement our existing product lines and allow us to expand our presence in the global market has proven to be a very effective strategy,” stated SP Industries CEO, Bill Downs. Downs continued by saying, “Bel-Art Products, which will continue operating under its own name, has done a superb job of building brand equity, developing a robust stream of innovative new products, and working with its channel partners to effectively serve the market. We are excited at the increased opportunities to grow market share and will cross-market across brands and leverage each organization’s expertise in product development, operations, finance, and supply chain management.”
Brad Mahood, Chief Operating Officer of Bel-Art, will play a key leadership role in sales, marketing, and product management at the corporate level. Additionally, David Landsberger, President of Bel-Art Products, will join the Board of Directors for SP Industries.
Symmetry-breaking Method Opens Way for Bioactive CompoundsNews
EPFL chemists have developed a new catalytic method for symmetry breaking. Published in Angewandte Chemie, the method can help synthesize important building blocks for bioactive compounds such as anticancer drugs.READ MORE
Scientists Report The Development of a Potent New Medicine to Fight AddictionNews
Scientists report the development of a potent new medicine to fight addiction.READ MORE
Evolution Threatens Efficient Bioproduction Scale-UpNews
The transition towards sustainable biobased chemical production is important for green growth, but productivity and yield of engineered cells frequently decrease in large industry-scale fermentation. According to a new study, the role of evolution has been underestimated in limiting bioprocesses.